Biotech Scan
Scan
Biotech Scan
raw scan snapshot — prices as of scan date, not live 45 rows · screens, not recommendations superseded by2026-04-26-biotech-scanported fromresearch/classic/scans/_archive/2026-03-24-biotech-scan.mdscan slugbiotech-scansource typescan-archive
Biotech in broad distribution — ABBV RSI 28, BMRN RSI 29, MDT RSI 30, A RSI 28 join the oversold ranks. MRNA (+58% 3M) and EXAS (RSI 76) are lone strong-up outliers. NVO death cross deepens (-55% from high). Gene editing names in structural decline.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 BEARISH — Broad sector weakness, most large-cap pharma and biotech oversold or approaching |
| Leaders | MRNA ($51.60, RSI 52, +57.6% 3M, strong-up), EXAS ($104.96, RSI 76↑, +41% vs SMA200), PTGX ($98.85, RSI 62, +36% vs SMA200) |
| Laggards | A ($110.47, RSI 28↓), ABBV ($204.91, RSI 28↓), BMRN ($54.25, RSI 29↓), SRPT ($16.74, -83% from high) |
Price Table
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | 3M% | Trend | Signal |
|---|---|---|---|---|---|---|---|---|
| EXAS | $104.96 | 76 ↑ | +1.3% | +0.3% | +1.5% | +3.1% | strong-up ✨ | ⚠️ Overbought |
| PTGX | $98.85 | 62 | +5.4% | +5.2% | +19.4% | +13.1% | strong-up ✨ | 🔒 Hold |
| MRNA | $51.60 | 52 | -2.9% | -6.7% | +2.1% | +57.6% | strong-up ✨ | 🔒 Hold |
| NTLA | $13.01 | 49 | -3.6% | +0.3% | +2.9% | +34.1% | strong-up ✨ | 🔍 Watch |
| EDIT | $2.37 | 55 | +4.3% | -8.9% | +32.4% | +1.7% | weak-up | 🔍 Watch |
| ILMN | $124.02 | 49 | -0.3% | +5.7% | +5.4% | -9.9% | weak-down | 🟡 Watch |
| BIIB | $183.81 | 47 | -1.2% | -0.8% | -5.8% | +4.2% | weak-down | 🟡 Watch |
| VRTX | $455.65 | 44 | -3.9% | -3.4% | -4.5% | -1.0% | weak-down | 🟡 Watch |
| TMO | $492.20 | 46 | -0.2% | +0.4% | -4.4% | -14.9% | down | 🟡 Watch |
| REGN | $738.08 | 42 | -3.1% | -3.8% | -4.4% | -5.7% | weak-down | 🟡 Watch |
| XBI | $120.60 | 41 | -3.6% | -1.4% | -3.4% | -4.2% | weak-down | 🟡 Watch |
| LEGN | $17.56 | 41 | -6.6% | -5.6% | -3.1% | -22.6% | strong-down 💀 | 🟡 Watch |
| AMGN | $349.97 | 38 | -5.0% | -4.3% | -8.6% | +5.6% | weak-down | 🟡 Watch |
| LABU | $142.26 | 39 | -12.4% | -4.7% | -12.8% | -19.2% | weak-down | 🟡 Watch |
| GILD | $137.06 | 37 | -4.8% | -5.1% | -6.6% | +9.7% | weak-down | 🟡 Watch |
| CRSP | $46.66 | 38 | -12.1% | -4.4% | -17.8% | -17.7% | strong-down 💀 | 🟡 Watch |
| ALNY | $314.53 | 40 | -2.4% | -1.8% | -6.4% | -22.9% | strong-down 💀 | 🟡 Watch |
| IQV | $165.02 | 38 | -2.9% | +0.6% | -0.4% | -26.5% | down | 🟡 Watch |
| BNTX | $87.69 | 36 | -11.2% | -1.7% | -20.4% | -4.9% | down | 🟡 Watch |
| DHR | $188.74 | 33 | -5.2% | +2.0% | -9.9% | -17.1% | down | 🟡 Approaching Oversold |
| RARE | $20.03 | 34 | -8.8% | -8.0% | -11.8% | -42.4% | strong-down 💀 | 🟡 Watch |
| INCY | $90.61 | 33 | -6.0% | +0.3% | -10.6% | -10.0% | weak-down | 🟡 Approaching Oversold |
| NVO | $36.52 | 31 | -4.3% | -3.6% | -23.0% | -24.1% | strong-down 💀 | 🟡 Approaching Oversold |
| LLY | $901.47 | 30 ↓ | -7.8% | -5.1% | -13.5% | -16.2% | weak-down | 🟢 Oversold |
| IONS | $70.83 | 31 | -7.4% | -1.9% | -14.8% | -12.9% | weak-down | 🟡 Approaching Oversold |
| MDT | $86.85 | 30 ↓ | -4.6% | -2.0% | -10.2% | -10.1% | down | 🟢 Oversold |
| BMRN | $54.25 | 29 ↓ | -8.7% | -7.3% | -15.3% | -8.5% | down | 🟢 Oversold |
| ABBV | $204.91 | 28 ↓ | -7.9% | -8.0% | -10.3% | -10.2% | down | 🟢 Oversold |
| A | $110.47 | 28 ↓ | -5.4% | +0.1% | -10.1% | -20.1% | strong-down 💀 | 🟢 Oversold |
| DXCM | $66.73 | 42 | -4.2% | -3.5% | -8.7% | -0.9% | strong-down 💀 | 🟡 Watch |
| SRPT | $16.74 | 43 | -2.0% | -3.2% | -11.3% | -21.2% | strong-down 💀 | 🟡 Watch |
Entry Zones
| Stock | Entry Zone | RSI | Thesis |
|---|---|---|---|
| ABBV | $195-210 | 28 | Dividend aristocrat, deep oversold |
| LLY | $880-910 | 30 | GLP-1 leader at oversold — rare entry |
| BMRN | $52-56 | 29 | Rare disease leader, approaching capitulation |
| MDT | $84-88 | 30 | Medtech at deep discount |
Action Matrix
| Stock | Signal | Action | Notes |
|---|---|---|---|
| MRNA | ✨ Strong-Up | 🔒 Hold | Monster rally from lows, +58% 3M |
| EXAS | 🟠 Overbought | ⚠️ Don't Chase | RSI 76, extended |
| PTGX | ✨ Strong-Up | 🔒 Hold | +19% 30D, biotech leader |
| ABBV | 🟢 Oversold | 📈 Accumulate | RSI 28, quality pharma |
| LLY | 🟢 Oversold | 📈 Accumulate | RSI 30, GLP-1 king |
| NVO | 💀 Death Cross | 🔍 Watch | -55% from high, Ozempic competition fears |
| SRPT | 💀 Structural | ❌ Don't Buy | -83% from high |
Related
10 eventsNo direct external sources are attached to this read.